Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Microprojection array patch for transdermal delivery of vascular endothelial growth factors

A technology of micro-protrusions and protruding elements, which is applied in the directions of drug delivery, sheet-like delivery, and devices introduced into the body, etc., can solve problems such as limited efficiency

Inactive Publication Date: 2007-10-03
ALZA CORP
View PDF40 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these approaches have limited efficiency in increasing transdermal protein flux due to their size, at least for larger proteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microprojection array patch for transdermal delivery of vascular endothelial growth factors
  • Microprojection array patch for transdermal delivery of vascular endothelial growth factors
  • Microprojection array patch for transdermal delivery of vascular endothelial growth factors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0265] The following examples are given to enable those skilled in the art to more clearly understand and apply the present invention. They are not to be considered as limitations on the scope of the invention, but merely to represent typical embodiments thereof.

VEGF preparations

[0266] The following studies were performed to develop suitable assays and demonstrate the suitability of VEGF-based reagent formulations for coating transdermal delivery microprojection arrays. VEGF was obtained from Scios in a volume of 110 mL (Scios lot #8331:058 rework #1). 100 mL of this solution (@1.82 mg VEGF / mL) was prepared in a 3:1 weight ratio of sucrose and VEGF, and packed into four 50 mL centrifuge tubes, each containing 25 mL of liquid formulation. After lyophilization, each powder was reconstituted with 2 mL of WFI, mixed and loaded into a 10000 MWCO dialysis card. The concentrate was exchanged twice in 1 L against 2 mM citrate buffer (pH 4.6) at 2-8° C., at least 12 h per exch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
melting pointaaaaaaaaaa
boiling pointaaaaaaaaaa
Login to View More

Abstract

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or assembly) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the VEGF-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Description

field of invention [0001] The present invention generally relates to transdermal agent delivery systems and methods. More specifically, the present invention relates to devices and methods for the transdermal delivery of vascular endothelial growth factor (VEGF)-based agents. Background of the invention [0002] It is well known that preeclampsia is a syndrome of hypertension, edema and proteinuria. Preeclampsia affects 5 to 10% of pregnant women and is responsible for nearly all fetal morbidity and mortality. Preeclampsia also accounts for at least 200,000 maternal deaths worldwide each year. [0003] Preeclampsia can vary in severity, from mild to life-threatening. Mild preeclampsia can be managed with bed rest and frequent monitoring. For moderate to severe cases, hospitalization is recommended and blood pressure medication or anticonvulsant medication is recommended to prevent seizures. If the life-threatening situation of the mother or fet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K38/18A61M37/00
CPCA61K47/26A61M2037/0023A61M2037/0061A61K9/0021A61M37/0015A61K38/1866A61M37/00A61P15/00A61P15/08A61P43/00
Inventor M·阿梅里M·J·N·科尔米尔Y·-F·马P·达多纳F·斯通班克斯
Owner ALZA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com